Dagandang, Jeraldine A.
HRN: 23-01-56 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/11/2023
CO-AMOXICLAV 625MG (TAB)
05/11/2023
05/18/2023
PO
625mg
BID
2nd Degree Laceration
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes